The study demonstrated that non-progressing BE lesions had small localized deletions at fragile sites, such as FHIT, WWOX, CDKN2A, and 9p arm loss/copy neutral loss of heterozygosity (LOH) (51). The gene discussed is CDKN2A; the disease is Barrett esophagus.